Published in JAMA on March 13, 1991
The Study of Barrett's Esophagus: What Are the Factors of Progression (BEST) | NCT00586404
Epidemiology of gastric cancer. World J Gastroenterol (2006) 7.67
Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst (2008) 6.00
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol (2006) 3.28
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol (1999) 2.88
Environmental causes of esophageal cancer. Gastroenterol Clin North Am (2009) 2.80
Helicobacter pylori and gastric diseases. BMJ (1998) 2.40
Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut (1998) 2.38
Increasing incidence of Barrett's oesophagus in the general population. Gut (2005) 2.34
Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer (2009) 2.33
Identifying intestinal metaplasia at the squamocolumnar junction by using optical coherence tomography. Gastrointest Endosc (2006) 2.31
Abdominal obesity, ethnicity and gastro-oesophageal reflux symptoms. Gut (2006) 2.28
A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer (2000) 2.27
Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol (2001) 2.21
Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut (2008) 2.08
Is esophageal adenocarcinoma occurring late after antireflux surgery due to persistent postoperative reflux? World J Surg (2007) 2.07
Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut (2001) 2.05
Treatment outcomes of resected esophageal cancer. Ann Surg (2002) 2.03
Trends in esophageal adenocarcinoma incidence and mortality. Cancer (2012) 2.03
No association between colon cancer and adenocarcinoma of the oesophagus in a population based cohort study in Sweden. Gut (1999) 2.03
Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res (2011) 2.00
Opposing time trends of peptic ulcer and reflux disease. Gut (1998) 1.99
Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg (2000) 1.98
Declining death rates reflect progress against cancer. PLoS One (2010) 1.91
Intestinal metaplasia at the squamocolumnar junction in patients attending for diagnostic gastroscopy. Gut (1997) 1.88
Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut (2002) 1.84
Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. Gut (2003) 1.81
Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest (1996) 1.81
Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil (2011) 1.79
Short segment Barrett's oesophagus: prevalence, diagnosis and associations. Gut (1997) 1.75
Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut (2005) 1.74
A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut (2001) 1.72
Body mass index and Barrett's oesophagus in women. Gut (2009) 1.70
Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer (2006) 1.70
FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci U S A (2001) 1.67
Dysfunctional transforming growth factor-β signaling with constitutively active Notch signaling in Barrett's esophageal adenocarcinoma. Cancer (2011) 1.63
Cost effectiveness of detecting Barrett's cancer. Gut (1996) 1.63
Patterns of gastritis in patients with gastro-oesophageal reflux disease. Gut (1999) 1.63
Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut (2001) 1.62
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer (2005) 1.61
Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer (1997) 1.61
Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut (2004) 1.60
Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg (1997) 1.58
Changes of Esophagogastric Junctional Adenocarcinoma and Gastroesophageal Reflux Disease Among Surgical Patients During 1988-2012: A Single-institution, High-volume Experience in China. Ann Surg (2016) 1.57
Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut (2002) 1.57
Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol (2000) 1.57
Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut (2007) 1.57
Worldwide Inverse Association between Gastric Cancer and Esophageal Adenocarcinoma Suggesting a Common Environmental Factor Exerting Opposing Effects. Am J Gastroenterol (2016) 1.54
Esophageal Adenocarcinoma and Its Rare Association with Barrett's Esophagus in Henan, China. PLoS One (2014) 1.53
Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol (2012) 1.53
Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut (2007) 1.52
Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut (1995) 1.52
Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. Gut (2001) 1.49
Inflammation of the gastro-oesophageal junction (carditis) in patients with symptomatic gastro-oesophageal reflux disease: a prospective study. Gut (1999) 1.48
Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut (2000) 1.46
Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst (1999) 1.44
Early gastric cancer shows different associations with adipose tissue volume depending on histological type. Gastric Cancer (2008) 1.42
MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.42
Comparative acceptability of transnasal esophagoscopy and esophageal capsule esophagoscopy: a randomized, controlled trial in veterans. Gastrointest Endosc (2014) 1.41
A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer (2008) 1.41
Effect of proton pump inhibitor therapy on inflammatory changes in the gastric cardia (carditis). Dig Dis Sci (2007) 1.39
Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc (2005) 1.37
Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer (2010) 1.36
Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg (2007) 1.35
MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res (2009) 1.35
Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut (2001) 1.34
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med (2004) 1.33
The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther (2012) 1.33
Comparisons of Gastric Cancer Treatments: East vs. West. J Gastric Cancer (2012) 1.33
Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut (2003) 1.32
NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg (2004) 1.31
Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev (2009) 1.30
A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. Mol Cell Proteomics (2010) 1.30
What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut (2004) 1.29
Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol (2013) 1.28
Clinicopathological analysis of patients with gastric cancer in 1200 cases. World J Gastroenterol (2001) 1.27
Intrathoracic leaks following esophagectomy are no longer associated with increased mortality. Ann Surg (2005) 1.25
Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates. Ann Surg (2006) 1.24
Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg (2003) 1.23
New approaches to treating oesophageal cancer. BMJ (1994) 1.22
Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas. Br J Cancer (1999) 1.22
Survival in stomach cancer is improving: results of a nationwide population-based Swedish study. Ann Surg (1999) 1.22
Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center. World J Surg (2009) 1.20
Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology (2008) 1.19
Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study. BMC Cancer (2012) 1.19
Psychosocial working conditions and the risk of esophageal and gastric cardia cancers. Eur J Epidemiol (2004) 1.18
Oesophageal cancer--an overview. Nat Rev Gastroenterol Hepatol (2013) 1.18
Transhiatal versus transthoracic esophagectomy for esophageal cancer. World J Gastroenterol (2010) 1.18
Outcomes after surgery for esophageal cancer. Gastrointest Cancer Res (2007) 1.18
Proximal gastric cancers resected via a transabdominal-only approach. Results and comparisons to distal adenocarcinoma of the stomach. Ann Surg (1997) 1.18
Food group intake and risk of subtypes of esophageal and gastric cancer. Int J Cancer (2008) 1.17
Gastric cancer: an infectious disease. Infect Dis Clin North Am (2010) 1.17
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol (2011) 1.16
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer (2005) 1.15
Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. Br J Cancer (1998) 1.14
Proton pump inhibitors for Barrett's oesophagus. Gut (2000) 1.14
Relation between gastric cancer and previous peptic ulcer disease. Gut (1997) 1.14
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
Cancer burden in the year 2000. The global picture. Eur J Cancer (2001) 10.47
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer (1998) 10.17
Rising incidence of renal cell cancer in the United States. JAMA (1999) 9.57
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature (2000) 8.96
Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res (1988) 7.30
Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med (1969) 6.54
A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 6.39
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (1999) 5.09
The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med (1996) 4.81
Solid cancers after bone marrow transplantation. N Engl J Med (1997) 4.62
Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst (1993) 4.59
Lung cancer. Cancer (1995) 4.50
Snuff dipping and oral cancer among women in the southern United States. N Engl J Med (1981) 4.33
Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1997) 4.09
International trends and patterns of prostate cancer incidence and mortality. Int J Cancer (2000) 3.73
Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med (2000) 3.72
Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1998) 3.66
Agricultural herbicide use and risk of lymphoma and soft-tissue sarcoma. JAMA (1986) 3.63
Risk of cancer in renal-transplant recipients. Lancet (1973) 3.36
Cancer risk in users of calcium channel blockers. Hypertension (1997) 3.30
Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst (1996) 3.26
An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res (1998) 3.22
A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control (2001) 3.13
Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet (1977) 3.05
Cancer incidence and mortality trends in the United States: 1935-74. J Natl Cancer Inst (1978) 3.01
Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA (1997) 3.00
Clues to cancer etiology from studies of farmers. Scand J Work Environ Health (1992) 2.98
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst (1996) 2.78
Recent cancer trends in the United States. J Natl Cancer Inst (1995) 2.76
Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst (2001) 2.73
Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA (1993) 2.71
The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA (1995) 2.68
Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer (1999) 2.66
Population attributable risk of renal cell cancer in Minnesota. Am J Epidemiol (1998) 2.65
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
A population-based case-control study of childhood leukemia in Shanghai. Cancer (1988) 2.59
Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA (1998) 2.55
Socioeconomic and racial differences in lung cancer incidence. Am J Epidemiol (1983) 2.54
Arsenic and respiratory cancer in man: an occupational study. J Natl Cancer Inst (1969) 2.50
International trends and patterns of primary liver cancer. Int J Cancer (2001) 2.50
Tobacco use and prostate cancer: 26-year follow-up of US veterans. Am J Epidemiol (1991) 2.49
Geographic patterns of lung cancer: industrial correlations. Am J Epidemiol (1976) 2.45
Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (1998) 2.43
Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst (1999) 2.38
Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States. BMJ (2012) 2.38
Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev (2002) 2.36
Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst (2000) 2.35
Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer (2009) 2.33
Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst (2000) 2.32
Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol (2001) 2.30
Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst (1969) 2.30
Declining lung cancer rates among young men and women in the United States: a cohort analysis. J Natl Cancer Inst (1989) 2.28
Cancer mortality among chemists. J Natl Cancer Inst (1969) 2.28
Association of breast cancer and cervical cancer incidence with income and education among whites and blacks. J Natl Cancer Inst (1980) 2.21
Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med (1977) 2.20
Fluoridated drinking water and the occurrence of cancer. J Natl Cancer Inst (1976) 2.19
A population--based case--control study of renal cell carcinoma. J Natl Cancer Inst (1984) 2.17
Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev (2001) 2.14
Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst (1998) 2.13
Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (2001) 2.13
Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers. J Natl Cancer Inst (1997) 2.12
Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst (1987) 2.12
Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst (1976) 2.11
Risk factors for esophageal cancer in Shanghai, China. I. Role of cigarette smoking and alcohol drinking. Int J Cancer (1994) 2.09
Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst (1997) 2.06
Synthetic sweetener consumption and bladder cancer trends in the United States. Nature (1970) 2.05
The influence of cigarette smoking, alcohol, and green tea consumption on the risk of carcinoma of the cardia and distal stomach in Shanghai, China. Cancer (1996) 2.05
Geographic patterns of oral cancer in the United States: etilogic implications. J Chronic Dis (1977) 2.02
Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst (1987) 2.02
Solid tumors after chronic lymphocytic leukemia. Blood (2001) 2.01
Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst (1987) 2.01
Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control (2000) 2.00
Passive smoking and lung cancer. J Natl Cancer Inst (1986) 1.99
Smoking, air pollution, and the high rates of lung cancer in Shenyang, China. J Natl Cancer Inst (1989) 1.99
A population-based case-control study of thyroid cancer. J Natl Cancer Inst (1987) 1.98
Epidemiology of uterine cervical cancer. J Chronic Dis (1986) 1.97
Epidemiology of human leukemia: recent observations. J Natl Cancer Inst (1967) 1.97
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev (2001) 1.95
Indoor radon and lung cancer in China. J Natl Cancer Inst (1990) 1.95
Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. J Natl Cancer Inst (1998) 1.91
Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res (1991) 1.89
Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer (2007) 1.87
Incidence of colorectal carcinoma in the U.S.: an update of trends by gender, race, age, subsite, and stage, 1975-1994. Cancer (1999) 1.84
Lung cancer among Chinese women. Int J Cancer (1987) 1.83
Tobacco and alcohol use and oral cancer in Puerto Rico. Cancer Causes Control (1999) 1.83
Cancer incidence trends in urban shanghai, 1972-1994: an update. Int J Cancer (1999) 1.83
Lung cancer after employment in shipyards during World War II. N Engl J Med (1978) 1.82
Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer (1997) 1.82
Breast cancer risk factors among screening program participants. J Natl Cancer Inst (1979) 1.81
Racial differences in risk of oral and pharyngeal cancer: alcohol, tobacco, and other determinants. J Natl Cancer Inst (1993) 1.80
Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst (1992) 1.79
Patterns of occurrence of the leukaemias. Eur J Cancer (1995) 1.77